# 60-Day Governed Automation Pilot

## Proposed Engagement
- Status: sellable-now
- Duration: 60 days
- Recommended commercial model: Recommended synthetic-pilot range: $125k-$350k; $350k-$500k when multiple workflows, custom diligence, or executive proof packets expand scope
- Target buyer: Enterprise healthcare teams validating workflow value, trust, and human-review design before integration
- Request route: /pilot?offer=synthetic-pilot-evaluation

## Objective
Run a selected workflow through deterministic synthetic evidence, AgentOS orchestration, TrustQA, observability, and executive review.

## Deliverables
- Configured synthetic workflow packet
- AgentOS orchestration and approval map
- Atlas Trust Cards and proof packet
- Measured synthetic workflow outcome report
- Protected-pilot readiness decision register

## Included Product Proof
- [CarePath Access Operations Demo](/demos/carepath-access-operations): Demonstrate how a fragmented high-risk follow-up queue becomes a reviewable operational routing packet.
- [DocuTwin Documentation Review Demo](/demos/docutwin-documentation-review): Demonstrate draft-only documentation support that preserves authorship, source trace, missing context, and review control.
- [PayerIQ Documentation Readiness Demo](/demos/prior-authorization-support): Demonstrate how a synthetic authorization scenario becomes a scored documentation-gap packet, reviewer queue, audit trace, and prepare-only workflow handoff.
- [TrialCore Research Operations Demo](/demos/trialcore-research-operations): Demonstrate an explainable synthetic eligibility review queue with criteria trace and evidence-gap visibility.

## Decision Metrics
- Time and friction baseline compared
- Trust and trace completeness measured
- Escalation and override design validated
- Protected-pilot business case approved or declined

## Buyer Inputs
- Named sponsor, workflow owner, and review team
- Approved synthetic scenario and success metrics
- Current-state process documentation without PHI
- Security, governance, and interoperability constraints

## Governance Gates
- Synthetic data only
- Human review before every external action
- Audit and blocked-action evidence retained
- No production connector access

## Production Exclusions
- No diagnosis or treatment
- No payer submission
- No patient outreach
- No production medical-record processing

## Product Boundary
SCRIMED demos and pilot programs are governed synthetic evaluations for enterprise buyers. They do not ingest live PHI, diagnose, treat, submit payer transactions, contact patients, mutate production records, or autonomously execute clinical care.

This non-binding proposal is a starting point for enterprise scoping. Final scope, pricing, security requirements, legal terms, success criteria, and production permissions require written buyer and SCRIMED approval.